Receptor Protein-Tyrosine Kinases
"Receptor Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.
Descriptor ID |
D020794
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400 D12.776.543.750.060
|
Concept/Terms |
Receptor Protein-Tyrosine Kinases- Receptor Protein-Tyrosine Kinases
- Kinases, Receptor Protein-Tyrosine
- Protein-Tyrosine Kinases, Receptor
- Receptor Protein Tyrosine Kinases
- PTK Receptors
- Receptors, PTK
- Receptor Protein-Tyrosine Kinase
- Kinase, Receptor Protein-Tyrosine
- Protein-Tyrosine Kinase, Receptor
- Receptor Protein Tyrosine Kinase
- Tyrosine Kinase Linked Receptors
- Tyrosine Kinase Receptors
- Protein-Tyrosine Kinase Receptor
- Receptor, Protein-Tyrosine Kinase
- Receptors, Protein-Tyrosine Kinase
- Protein-Tyrosine Kinase Receptors
- Receptors, Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Receptor Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Receptor Protein-Tyrosine Kinases".
- Receptor Protein-Tyrosine Kinases
- fms-Like Tyrosine Kinase 3
- Proto-Oncogene Proteins c-kit
- Proto-Oncogene Proteins c-met
- Proto-Oncogene Proteins c-ret
- Receptor Tyrosine Kinase-like Orphan Receptors
- Receptor, Epidermal Growth Factor
- Receptor, erbB-2
- Receptor, erbB-3
- Receptor, Fibroblast Growth Factor, Type 1
- Receptor, Fibroblast Growth Factor, Type 2
- Receptor, Fibroblast Growth Factor, Type 3
- Receptor, Fibroblast Growth Factor, Type 4
- Receptor, IGF Type 1
- Receptor, Insulin
- Receptor, Macrophage Colony-Stimulating Factor
- Receptor, trkA
- Receptor, trkB
- Receptor, trkC
- Receptors, Eph Family
- Receptors, Platelet-Derived Growth Factor
- Receptors, TIE
- Receptors, Vascular Endothelial Growth Factor
This graph shows the total number of publications written about "Receptor Protein-Tyrosine Kinases" by people in this website by year, and whether "Receptor Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 1 | 0 | 1 | 1994 | 2 | 2 | 4 | 1995 | 2 | 0 | 2 | 1996 | 1 | 1 | 2 | 1997 | 1 | 2 | 3 | 1998 | 1 | 2 | 3 | 1999 | 0 | 1 | 1 | 2000 | 2 | 0 | 2 | 2001 | 3 | 1 | 4 | 2002 | 3 | 3 | 6 | 2003 | 3 | 1 | 4 | 2004 | 4 | 3 | 7 | 2005 | 2 | 4 | 6 | 2006 | 4 | 1 | 5 | 2007 | 0 | 2 | 2 | 2008 | 0 | 6 | 6 | 2009 | 2 | 0 | 2 | 2010 | 3 | 3 | 6 | 2011 | 4 | 3 | 7 | 2012 | 5 | 0 | 5 | 2013 | 3 | 3 | 6 | 2014 | 3 | 1 | 4 | 2015 | 2 | 3 | 5 | 2016 | 7 | 2 | 9 | 2017 | 4 | 1 | 5 | 2018 | 2 | 1 | 3 | 2019 | 2 | 1 | 3 | 2020 | 2 | 2 | 4 | 2021 | 2 | 0 | 2 | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor Protein-Tyrosine Kinases" by people in Profiles.
-
Iida M, McDaniel NK, Kostecki KL, Welke NB, Kranjac CA, Liu P, Longhurst C, Bruce JY, Hong S, Salgia R, Wheeler DL. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022 Apr 23; 22(1):447.
-
Lee YH, Lee MM, De Silva DM, Roy A, Wright CE, Wong TK, Costello R, Olaku O, Grubb RL, Agarwal PK, Apolo AB, Bottaro DP. Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. PLoS One. 2021; 16(7):e0241766.
-
Murugesan S, Murugesan J, Palaniappan S, Palaniappan S, Murugan T, Siddiqui SS, Loganathan S. Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis. Curr Cancer Drug Targets. 2021; 21(1):55-69.
-
Chaudagar KK, Landon-Brace N, Solanki A, Hieromnimon HM, Hegermiller E, Li W, Shao Y, Joseph J, Wilkins DJ, Bynoe KM, Li XL, Clohessy JG, Ullas S, Karp JM, Patnaik A. Cabozantinib Unlocks Efficient In Vivo Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors. Mol Cancer Ther. 2021 02; 20(2):438-449.
-
Nichetti F, Lo Russo G, Prelaj A, Provenzano L, de Braud F, Cabiddu M, Garassino MC, Petrelli F. ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients? Thromb Res. 2020 10; 194:176-177.
-
McDaniel NK, Iida M, Nickel KP, Longhurst CA, Fischbach SR, Rodems TS, Kranjac CA, Bo AY, Luo Q, Gallagher MM, Welke NB, Mitchell KR, Schulz AE, Eckers JC, Hu R, Salgia R, Hong S, Bruce JY, Kimple RJ, Wheeler DL. AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clin Cancer Res. 2020 08 15; 26(16):4349-4359.
-
Möller L, Regnier G, Labro AJ, Blunck R, Snyders DJ. Determining the correct stoichiometry of Kv2.1/Kv6.4 heterotetramers, functional in multiple stoichiometrical configurations. Proc Natl Acad Sci U S A. 2020 04 28; 117(17):9365-9376.
-
Luke JJ, Olson DJ, Allred JB, Strand CA, Bao R, Zha Y, Carll T, Labadie BW, Bastos BR, Butler MO, Hogg D, Munster PN, Schwartz GK. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020 02 15; 26(4):804-811.
-
Mills KA, Quinn JM, Roach ST, Palisoul M, Nguyen M, Noia H, Guo L, Fazal J, Mutch DG, Wickline SA, Pan H, Fuh KC. p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts. Sci Rep. 2019 03 18; 9(1):4762.
-
Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 04; 20(4):581-590.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|